Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy ...
Jan 29, 2015